06 February 2023

Strong growth is to be expected in the use of cell therapies for acute lymphocytic leukaemia, according to a new analysis.

The data analytics company GlobalData's report “Acute Lymphocytic Leukaemia (ALL): Cell Therapies 15-Market Assessment and Forecast”, was released on Monday.

It predicts growth at a compound annual rate of 5% over the next decade for ALL pharmaceuticals across the world’s eight major markets.

Progress on treatments for this commonly diagnosed form of leukaemia has focused on cell therapies. The chimeric antigen receptor (CAR) T-cell therapy market alone is predicted by GlobalData to account for 40% of the total ALL market, reaching 1.2bn US dollars in 2031.

The report states that the anti-CD19 CAR-T therapy Kymriah, produced by Novartis, is expected to remain the market-leading ALL brand.

“The approval of Kymriah and Gilead’s Tecartus has revolutionised the ALL therapeutic landscape, with patients who previously had a very poor prognosis entering long-term remission.” said Dr Avigayil Chalk of GlobalData.

Dr Chalk added: “Expansion into additional patient populations for these already approved CAR-Ts, as well as the anticipated approval of next-generation CAR-Ts over the next decade, make CAR-Ts the leading class of therapy in the ALL setting.”

Overall, there are 118 different cell therapies currently undergoing clinical trials for ALL patients, of which 82 are CAR-T cell therapies.

“The ALL CAR-T pipeline is saturated,” warned Dr Chalk, “with more products in development than the market can sustain. To gain approval agents will have to outperform the marketed anti-CD19 CAR-Ts in clinical efficacy or provide a commercial advantage.”

Apart from CAR-T therapies, an ex vivo expanded stem cell transplant product called NiCord, made by Gamida Cell, is predicted to be the leading cell therapy brand.

“NiCord is now set to become the standard of care for patients without a matched transplant donor,” Dr Chalk concluded.


Source: GlobalData

Link: https://www.globaldata.com/media/pharma/car-t-cells-to-hold-over-40-of-acute-lymphocytic-leukemia-market-by-2031/

Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News.